Alumis Inc (ALMS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.61 (-2.69%), Market cap $2.92B, 52-week low–high $2.80 ~ $29.98.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and c
Financial statements, price targets, institutional (13F) holdings and related news for Alumis Inc are updated in real time on BlackAll Trade.
Alumis Inc trades at $7.61 (-2.69%). Real-time quotes and charts are available on BlackAll Trade.
Alumis Inc has a market cap of about $2.92B.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2